Updated May 20, 2018 12:18:24 A new drug from a supplement company is offering a new way to treat ADD and depression, as well as boosting cognition.
In the latest twist in the saga of ADHD and depression medications, Nutrafin is making headlines after it was approved by the Food and Drug Administration for the treatment of ADHD, the same drug that has been used for more than two decades to treat bipolar disorder.
The FDA is currently reviewing the drug and has yet to decide if it is approved.
But the FDA said in a statement that NutraFins “provides a clinically proven treatment for ADHD, and that is an important distinction for us, given that this drug also has been shown to be effective in treating ADD.”
The FDA has approved a range of drugs for ADHD to treat attention deficit hyperactivity disorder, bipolar disorder, attention deficit/hyperactivity disorder and depression.
But in the past, the agency has only approved drugs to treat ADHD, mood disorders and attention deficit disorders.
“We are seeing more and more of these treatments being approved by FDA, and the more they are approved, the more patients we see with these disorders,” said Jennifer Fagan, the director of the ADHD Center at Johns Hopkins University.
“It is a great opportunity for the FDA to approve a treatment that is safe, effective and not only safe, but also effective.”
The drug, called NutraFin, is being touted as a breakthrough in ADHD treatment.
It was originally designed as a treatment for bipolar disorder and bipolar disorder combined.
But it can treat ADD, depression and other disorders as well.
The drug has been tested in humans for more a decade and has been approved by a number of other regulatory agencies.
The new drug, which is a combination of two of the most popular ADHD medications, is marketed as a supplement that is taken orally or as a liquid form that can be taken by mouth.
It contains a variety of nutrients, including Vitamin C and vitamin E.
In an interview with ABC News, Dr. Michael Gorman, a professor of psychiatry at the University of Pennsylvania, said that while the supplement is being marketed as an ADHD drug, the real-world data is showing that it’s actually a combination treatment.
He said there are several factors that contribute to the effectiveness of supplements.
The drug is designed to be taken orally, so there are not many side effects.
And there are nutrients in it that are actually really beneficial to the brain.
Gorman said that even though the FDA is reviewing the new drug and there are no other ADHD medications approved, he thinks it will be approved.
“I think that it will eventually be approved because of the combination of vitamins and minerals,” Gorman said.
The supplement is also a combination, with other ADHD medication, that’s been shown in other studies to work better than a single medication.
Dr. Pauline Paz, a pediatric psychiatrist at the Johns Hopkins School of Medicine, said there is no need to panic.
Paz said there’s no reason for patients to worry because the new drugs work together and are safe.
She added that it is important to remember that ADHD medications can cause side effects and can increase the risk of developing certain conditions.
“People should be taking supplements for their ADHD,” Paz said.
“If they have any issues, just ask your doctor.
But we are not saying that you need to go to the ER or to have an emergency room.
But just be careful.”
Dr. Daniel Mancini, director of neurodevelopmental disorders at Johns’ Children’s Hospital, said he has never seen a case of a child who developed ADHD with NutraFeins.
He said the fact that Nutralin is not being marketed to treat the disorder itself is a good sign.
“This is a safe, inexpensive and effective supplement that works,” Mancino said.
Gogan, the psychiatrist, said the FDA could change its mind if Nutrafins is shown to work in more patients.
He noted that it may not be necessary to go back to the doctor if there’s a mild case of ADHD.
“That doesn’t mean that there are all those other medications that have been shown not to work,” Gogan said.
“If Nutrafuals worked as well in patients with mild cases, it would make it a lot easier to recommend it,” he said.
Mancino also said that there is potential for NutraFuals to work for adults who have ADHD and bipolar disorders.
He cautioned that he does not know of any adult patients who have responded to NutraFains.
“It is very exciting that this product is getting approval,” he added.